The world is mobilized against antimicrobial resistance, elected by the World Health Organization (WHO) as one of the top ten threats to global public health. Without action, it is estimated that by 2050 the problem will cause the loss of 10 million lives worldwide each year and an economic loss of $ 100 trillion. This year, the main mobilization takes place from November 18 to 24, during World Antimicrobial Awareness Week.
The action is supported by the International Coalition of Medicines Regulatory Authorities (ICMRA), formed by 29 drug regulatory authorities, including Anvisa, as well as WHO itself.
With the slogan “The future of antibiotics depends on us all”, the goal of the global campaign is to leverage the individual actions of ICMRA members to inform society and combat the occurrence of antimicrobial resistance, avoiding health complications and deaths.
One of the efforts this year was the publication of an ICMRA statement targeting the drug industry, health professionals (human and animal), global health leaders, researchers and the media. The document calls for various segments to make collective efforts to undertake joint outreach actions on the risks of antimicrobial resistance.
Click here for the ICMRA statement.
Anvisa's continuous actions
Anvisa is a member of ICMRA and supports the fight against antimicrobial resistance. In 2012, the body established the Microbial Resistance Technical Chamber (Catrem), with the purpose of advising the Collegiate Board (Dicol) in the elaboration of norms and measures for the monitoring, control and prevention of microbial resistance in health services in Brazil. Brazil.
In 2017, the National Guideline for the Elaboration of the Antimicrobial Use Management Program in Health Services was published, with the objective of guiding professionals in the area in the design and implementation of programs. As early as 2019, Anvisa initiated the Brazil Stewardship Project, which aims to assess the national landscape of these management programs in hospitals with adult intensive care units (ICUs). In addition, Anvisa continuously works on the preparation of materials and the promotion of educational actions on the subject.
In Brazil, microbial resistance is monitored in 2,200 ICU-bed hospitals. The area responsible for this work is the Health Services Surveillance and Monitoring Management (GVIMS) of the General Health Services Technology Management (GGTES), which periodically publishes data on the subject through national newsletters.
Understand What Antimicrobial Resistance Is
Inadequate consumption of certain pharmaceutical products causes what health authorities call antimicrobial resistance, a phenomenon characterized by the development of superbugs capable of resisting the effects of disease treatments.
This resistance is created when bacteria are repeatedly exposed to the use of one or more products, such as antibiotics and antivirals, among others. Over time, the etiological agents that cause the illnesses are no longer impacted and medicines become limited in the fight against the disease.
The problem has a number of consequences for the entire population, such as prolonged illness and increased mortality and hospitalization rates, as well as the inefficiency of preventive therapies.
Source: http://portal.anvisa.gov.br/noticias?p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_col_id=column-2&p_p_col_pos=1&p_p_col_count=2&_101_INSTANCE_FXrpx9qY7FbU_groupId=219201&_101_INSTANCE_FXrpx9qY7FbU_urlTitle=resistencia-antimicrobiana-e-ameaca-global-diz-oms&_101_INSTANCE_FXrpx9qY7FbU_struts_action=%2Fasset_publisher%2Fview_content&_101_INSTANCE_FXrpx9qY7FbU_assetEntryId=5696321&_101_INSTANCE_FXrpx9qY7FbU_type=content